1. Scrip
  2. >>New Products

Quite A Range: Adamas Ponders $10,000-$30,000 Price Tag For Gocovri

 
• By Mandy Jackson

The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.

ApproveOnKeyboard_1200x675

Adamas Pharmaceuticals Inc. has not finalized the pricing for its newly-approved Gocovri in the treatment of levodopa-induced dyskinesia in Parkinson's disease, but the company is using other Parkinson's therapies priced between $10,000 and $30,000 per year as benchmarks.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.